low-dose CNS-penetrant BACE inhibitor

90% red. of CSF A_ in Ph. II at 9.2 mg / discont.

from opt. vs. CatD and dose red. of prior leads

Journal of Medicinal Chemistry

Eli Lilly, Indianapolis, US


6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase II of clinical trial against AlzheimerĂ•s disease in 2016.…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: